Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. I… Read more
Tibet Weixinkang Medicine Co Ltd (603676) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.009x
Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) has a cash flow conversion efficiency ratio of 0.009x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥13.68 Million) by net assets (CN¥1.53 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tibet Weixinkang Medicine Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Tibet Weixinkang Medicine Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tibet Weixinkang Medicine Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tibet Weixinkang Medicine Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Archer Ltd.
LSE:0RBA
|
0.017x |
|
McBride plc
PINK:MCBRF
|
0.155x |
|
Saratoga Investama Sedaya
JK:SRTG
|
0.000x |
|
Blumar
SN:BLUMAR
|
0.058x |
|
ARIMA REAL EST.SOC. EO 10
F:3AZ
|
N/A |
|
FOS.TOUR.GRP EO-0001
F:6T8
|
N/A |
|
HELLOFRESH UNSP.ADS/025
F:HFG0
|
N/A |
|
Shenzhen RoadRover Technology Co Ltd
SHE:002813
|
-0.077x |
Annual Cash Flow Conversion Efficiency for Tibet Weixinkang Medicine Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Tibet Weixinkang Medicine Co Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.39 Billion | CN¥372.78 Million | 0.269x | +40.51% |
| 2023-12-31 | CN¥1.34 Billion | CN¥256.67 Million | 0.191x | -5.04% |
| 2022-12-31 | CN¥1.22 Billion | CN¥246.15 Million | 0.202x | +26.10% |
| 2021-12-31 | CN¥1.07 Billion | CN¥170.69 Million | 0.160x | +17.61% |
| 2020-12-31 | CN¥983.21 Million | CN¥133.70 Million | 0.136x | +18.93% |
| 2019-12-31 | CN¥930.05 Million | CN¥106.34 Million | 0.114x | +23.41% |
| 2018-12-31 | CN¥897.64 Million | CN¥83.17 Million | 0.093x | +25.59% |
| 2017-12-31 | CN¥858.04 Million | CN¥63.30 Million | 0.074x | -67.34% |
| 2016-12-31 | CN¥459.42 Million | CN¥103.79 Million | 0.226x | -20.48% |
| 2015-12-31 | CN¥402.93 Million | CN¥114.47 Million | 0.284x | -31.35% |
| 2014-12-31 | CN¥286.28 Million | CN¥118.47 Million | 0.414x | +15.75% |
| 2013-12-31 | CN¥247.78 Million | CN¥88.59 Million | 0.358x | -- |